title: Effect of lodoxamide on tear leukotriene levels in giant papillary conjunctivitis associated with ocular prosthesis.
abstract: Leukotrienes have been shown to play a role in the pathogenesis of ocular inflammatory and allergic reactions like vernal keratoconjunctivitis and contact lens-associated giant papillary conjunctivitis. This study was designed to determine leukotriene B4 (LTB4) and leukotriene C4 (LTC4) levels in the tears of patients with ocular prosthesis-associated giant papillary conjunctivitis (OP-GPC) and to evaluate the effects of lodoxamide 0.1% on tear LTB4 and LTC4 levels of OP-GPC patients. Tear LTB4 and LTC4 levels were determined by an ELISA technique in the tears of ten OP-GPC patients before and after treatment with lodoxamide 0.1% for one month. The results were compared with that of ten healthy control subjects. The mean tear LTB4 and LTC4 levels of the OP-GPC patients were significantly higher than those of the control group. After treatment with lodoxamide 0.1%, tear LTB4 and LTC4 levels of the OP-GPC patients decreased significantly. This is the first report of elevated LTB4 and LTC4 levels in tears of OP-GPC patients and it points to the possible role of leukotrienes in the immunopathogenesis of OP-GPC. The results also indicate that lodoxamide 0.1%, a mast cell membrane stabilizer, is effective in significantly reducing tear LTB4 and LTC4 levels in OP-GPC patients.
authors.affiliation: Department of Ophthalmology, School of Medicine, Başkent University, Ankara, Turkey. choroid@mailexcite.com
authors.forename: A
authors.initials: A
authors.lastname: Akman
authors.forename: M
authors.initials: M
authors.lastname: Irkeç
authors.forename: M
authors.initials: M
authors.lastname: Orhan
authors.forename: U
authors.initials: U
authors.lastname: Erdener
mesh_terms: D000293:Adolescent; D018926:Anti-Allergic Agents / Q000627:therapeutic use*; D003233:Conjunctivitis, Allergic / Q000188:drug therapy / Q000209:etiology / Q000378:metabolism*; D004797:Enzyme-Linked Immunosorbent Assay; D017234:Eye Evisceration; D005137:Eye, Artificial / Q000009:adverse effects*; D005260:Female; D006801:Humans; D007975:Leukotriene B4 / Q000378:metabolism*; D017997:Leukotriene C4 / Q000378:metabolism*; D008297:Male; D009883:Ophthalmic Solutions; D010072:Oxamic Acid / Q000031:analogs & derivatives* / Q000627:therapeutic use; D013666:Tears / Q000378:metabolism*
chemical_list: D018926:Anti-Allergic Agents; D009883:Ophthalmic Solutions; D007975:Leukotriene B4; D017997:Leukotriene C4; D010072:Oxamic Acid; C021702:lodoxamide ethyl